• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

门诊放射性碘治疗甲状腺癌:一种安全的核医学程序。

Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.

机构信息

Department of Radiology, School of Medicine, University of São Paulo, São Paulo, Brazil.

出版信息

Clin Nucl Med. 2011 Jun;36(6):440-5. doi: 10.1097/RLU.0b013e3182184fa0.

DOI:10.1097/RLU.0b013e3182184fa0
PMID:21552020
Abstract

PURPOSES

To evaluate the dosimetric effect of outpatient radioiodine therapy for thyroid cancer in members of a patient's family and their living environment, when using iodine-131 doses reaching 7.4 GBq. The following parameters were thus defined: (a) whole-body radiation doses to caregivers, (b) the production of contaminated solid waste, and (c) radiation potential and surface contamination within patients' living quarters.

METHODS

In total, 100 patients were treated on an outpatient basis, taking into consideration their acceptable living conditions, interests, and willingness to comply with medical and radiation safety guidelines. Both the caregivers and the radiation dose potentiality inside patients' residences were monitored by using thermoluminescent dosimeters. Surface contamination and contaminated solid wastes were identified and measured with a Geiger-Müller detector.

RESULTS

A total of 90 monitored individuals received a mean dose of 0.27 (±0.28) mSv, and the maximum dose registered was 1.6 mSv. The mean value for the potential dose within all living quarters was 0.31 (±0.34) mSv, and the mean value per monitored surface was 5.58 Bq/cm(2) for all the 1659 points measured. The overall production of contaminated solid wastes was at a low level, being about 3 times less than the exemption level indicated by the International Atomic Energy Agency.

CONCLUSIONS

This study indicates that the treatment of thyroid cancer by applying radioiodine activities up to 7.4 GBq, on an outpatient basis, is a safe procedure, especially when supervised by qualified professionals. This alternative therapy should be a topic for careful discussion considering the high potential for reducing costs in healthcare and improving patient acceptance.

摘要

目的

评估使用达到 7.4GBq 的碘-131 剂量为甲状腺癌患者家庭成员及其生活环境进行门诊放射性碘治疗的剂量学效应。因此定义了以下参数:(a)照顾者的全身辐射剂量,(b)污染固体废物的产生,以及(c)患者居住区内的辐射潜力和表面污染。

方法

总共为 100 名患者进行了门诊治疗,考虑到他们可接受的生活条件、兴趣以及遵守医疗和辐射安全指南的意愿。通过使用热释光剂量计监测照顾者和患者住所内的辐射剂量潜力。使用盖革-弥勒探测器识别和测量表面污染和污染固体废物。

结果

共监测 90 人,平均剂量为 0.27(±0.28)mSv,记录的最大剂量为 1.6mSv。所有居住区内潜在剂量的平均值为 0.31(±0.34)mSv,测量的 1659 个点中每个监测表面的平均值为 5.58Bq/cm²。污染固体废物的总体产生量处于较低水平,约为国际原子能机构规定的豁免水平的 3 倍。

结论

本研究表明,应用高达 7.4GBq 的放射性碘活度进行甲状腺癌的门诊治疗是一种安全的治疗方法,特别是在合格专业人员的监督下。这种替代治疗方法应作为一个话题进行仔细讨论,因为它有可能降低医疗保健成本并提高患者的接受程度。

相似文献

1
Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.门诊放射性碘治疗甲状腺癌:一种安全的核医学程序。
Clin Nucl Med. 2011 Jun;36(6):440-5. doi: 10.1097/RLU.0b013e3182184fa0.
2
Commentary on Willegaignon et al.: outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.关于维勒加尼翁等人的评论:甲状腺癌的门诊放射性碘治疗:一种安全的核医学程序。
Clin Nucl Med. 2011 Jun;36(6):446. doi: 10.1097/RLU.0b013e3182184fbb.
3
Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?门诊使用3.7和5.55GBq的碘化钠(¹³¹I)治疗分化型甲状腺癌是否安全?
Nucl Med Commun. 2009 Jul;30(7):533-41. doi: 10.1097/MNM.0b013e32832b79bc.
4
Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.甲状腺全切术后使用 1,110MBq 的 I-131 进行残余甲状腺消融: unsealed radioiodine therapy 后患者出院的监管考虑因素。
Ann Nucl Med. 2012 May;26(4):370-8. doi: 10.1007/s12149-012-0590-7. Epub 2012 Mar 27.
5
Outpatient therapeutic 131I for thyroid cancer.甲状腺癌的门诊治疗性131I
J Nucl Med Technol. 2005 Mar;33(1):28-30.
6
Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.接受放射性碘消融治疗的甲状腺癌患者的同居者所受辐射剂量:对辐射防护指南的依从性差但辐射暴露量低。
Nucl Med Commun. 2011 Sep;32(9):829-33. doi: 10.1097/MNM.0b013e328347f1c2.
7
Radioprotection using iodine-131 for thyroid cancer and hyperthyroidism: a review.使用碘-131对甲状腺癌和甲状腺功能亢进症进行辐射防护:综述
Clin J Oncol Nurs. 2008 Dec;12(6):905-12. doi: 10.1188/08.CJON.905-912.
8
Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.甲状腺癌的治疗:重点关注高剂量¹³¹I门诊治疗。
J Nucl Med Technol. 2002 Dec;30(4):165-71; quiz 172-3.
9
Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.甲状腺癌治疗中¹³¹I治疗的患者参数及其他辐射安全问题。
Health Phys. 2007 Dec;93(6):656-66. doi: 10.1097/01.HP.0000270274.66246.7e.
10
Dosimetry and thyroid cancer: the individual dosage of radioiodine.剂量学与甲状腺癌:放射性碘的个体剂量。
Endocr Relat Cancer. 2010 Jun 3;17(3):R161-72. doi: 10.1677/ERC-10-0071. Print 2010 Sep.

引用本文的文献

1
Radiation safety measures in diagnostic nuclear medicine, based on the potential radiation dose emitted by radioactive patients.基于放射性患者所发射的潜在辐射剂量的诊断核医学中的辐射安全措施。
Radiol Bras. 2023 Jan-Feb;56(1):13-20. doi: 10.1590/0100-3984.2022.0064.
2
HSA-MnO-I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma.HSA-MnO-I 联合成像与治疗间变性甲状腺癌。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221106557. doi: 10.1177/15330338221106557.
3
Do Current Radiation Safety Guidelines allow the Safe Release of a Thyroid Cancer Patient after High-dose Radioiodine Therapy? An Indian Perspective.
现行辐射安全指南是否允许甲状腺癌患者在接受高剂量放射性碘治疗后安全出院?印度视角。
Indian J Nucl Med. 2021 Apr-Jun;36(2):148-152. doi: 10.4103/ijnm.ijnm_210_20. Epub 2021 Jun 21.
4
Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient I Therapy for Differentiated Thyroid Cancer.分化型甲状腺癌门诊治疗后,包括运输和住宿在内的放射防护要点。
Thyroid. 2017 Dec;27(12):1558-1565. doi: 10.1089/thy.2017.0124.
5
Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles.通过二氧化硅纳米颗粒酸触发释放阿霉素靶向治疗甲状腺癌。
Int J Nanomedicine. 2017 Aug 21;12:5993-6003. doi: 10.2147/IJN.S137335. eCollection 2017.